Advanced

By Targets:	Aldose Reductase (3) Amyloid-β (5) Anaplastic lymphoma kinase (ALK) (1) Androgen Receptor (1) Antibody-Drug Conjugates (ADCs) (3) Antifolate (2) Apoptosis (2) Autophagy (1) Beta-secretase (2) Biochemical Assay Reagents (1) Btk (2) c-Fms (2) c-Kit (1) CDK (4) COX (2) Dihydrofolate reductase (DHFR) (1) Dipeptidyl Peptidase (2) DNA/RNA Synthesis (1) Drug Metabolite (1) Drug-Linker Conjugates for ADC (1) EGFR (4) Endogenous Metabolite (7) Epigenetic Reader Domain (1) Estrogen Receptor/ERR (3) Farnesyl Transferase (1) FLT3 (1) Fungal (2) GABA Receptor (2) GLP Receptor (1) GnRH Receptor (1) Hedgehog (1) HIF/HIF Prolyl-Hydroxylase (2) Histone Methyltransferase (2) Indoleamine 2,3-Dioxygenase (IDO) (1) Interleukin Related (1) IRAK (2) IRE1 (1) Isotope-Labeled Compounds (2) JAK (1) LIM Kinase (LIMK) (1) LXR (1) mGluR (1) nAChR (1) Notch (1) P-glycoprotein (1) Parasite (1) PARP (1) PD-1/PD-L1 (8) Phosphatase (1) PPAR (1) Reactive Oxygen Species (1) RET (1) ROS Kinase (1) SARS-CoV (1) Serotonin Transporter (1) SHP2 (1) Src (1) TAM Receptor (2) TGF-beta/Smad (1) TNF Receptor (2) Toll-like Receptor (TLR) (2) Trk Receptor (1) VEGFR (2) γ-secretase (1)
By Research Areas:	Cancer (63) Cardiovascular Disease (2) Infection (3) Inflammation/Immunology (15) Metabolic Disease (16) Neurological Disease (11)
Click Chemistry:	Alkynes (1)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-153422

PRMT5-IN-29	Histone Methyltransferase	Cancer
PRMT5-IN-29 is a potent and orally active PRMT5 Inhibitor with an IC₅₀ of 1.5 μΜ. PRMT5-IN-29 has the potential for advanced cancers research .

HY-P99807

Prolgolimab BCD-100	PD-1/PD-L1	Cancer
Prolgolimab (BCD-100) is a human IgG1 anti-PD-1 monoclonal antibody containing the Fc-silencing 'LALA' mutation. Prolgolimab can be used for the research of advanced melanoma .

HY-125647

10-Deazaaminopterin	Dihydrofolate reductase (DHFR)	Cancer
10-Deazaaminopterin is a potent inhibitor of dihydrofolate reductase. 10-Deazaaminopterin can used in study advanced cancer .

HY-119108

Emitefur

BOF-A2
Others Cancer

Emitefur is an orally active and potent anticancer drug. Emitefur can be used for advanced gastric cancer patients .

Emitefur BOF-A2	Others	Cancer
Emitefur is an orally active and potent anticancer drug. Emitefur can be used for advanced gastric cancer patients .

HY-147426

Zifcasiran ADS-007; ARO HIF2	HIF/HIF Prolyl-Hydroxylase	Cancer
Zifcasiran is a hypoxia-inducible factor (HIF) synthesis reducer. Zifcasiran shows antitumor activities and can be used in advanced renal cell carcinoma research .

HY-147426A

Zifcasiran sodium ADS-007 sodium; ARO HIF2 sodium	HIF/HIF Prolyl-Hydroxylase	Cancer
Zifcasiran sodium is a hypoxia-inducible factor (HIF) synthesis reducer. Zifcasiran sodium shows antitumor activities and can be used in advanced renal cell carcinoma research .

HY-153243

IACS-9439	c-Fms	Cancer
IACS-9439 is a potent, selective, and orally active CSF1R inhibitor with a K_i value of 1 nM inhibitor. IACS-9439 can be used for advanced solid tumors research .

HY-16050

Plitidepsin 2 Publications Verification Aplidine; PM90001	DNA/RNA Synthesis SARS-CoV	Infection Cancer
Plitidepsin (Aplidine) is a potent anti-cancer agent by targeting eEF1A2 ( K_D=80 nM) . Plitidepsin possesses antiviral activity and is against SARS-CoV-2 with an IC₉₀ of 0.88 nM. Plitidepsin is usually used for multiple myeloma and advanced cancer research, and has the potential for COVID-19 research .

HY-18614

LY900009	Notch γ-secretase	Cancer
LY900009 is a potent and orally active, First-in-class inhibitor of Notch signaling via selective inhibition of the γ-secretase protein (GSI). LY900009 inhibited Notch signalling in tumor cell lines and endothelial cells (IC₅₀ range: 0.005-20 nM). LY900009 can be used for advanced cancer research .

HY-149981

P-gp inhibitor 13	P-glycoprotein	Cancer
P-gp inhibitor 13 is a P-gp inhibitor. P-gp inhibitor 13 can reverse P-glycoprotein-mediated paclitaxel resistance in A2780/T cell. P-gp inhibitor 13 can be used for the research of advanced acute myeloid leukemia .

HY-P99475

Betifisolimab MSB-2311	PD-1/PD-L1	Cancer
Betifisolimab (MSB-2311) is a humanized monoclonal antibody directed against the immunosuppressive ligand PD-L1. Betifisolimab has the potential for advanced solid tumors and hematological malignancies research .

HY-N7628

Cassiaside C Toralactone 9-O-β-D-gentiobioside	Endogenous Metabolite	Metabolic Disease
Cassiaside C (Toralactone 9-O-β-D-gentiobioside) is a naphthopyrone isolated from the seed of Cassia tora and has inhibitory activity on advanced glycation end products (AGE) formation in vitro .

HY-151247

GnRH-R antagonist 1	GnRH Receptor	Cancer
GnRH-R antagonist 1 (compound 21a) is an orally safe and membrane-permeable GnRH-R antagonist with high binding affinity (IC₅₀=0.57 nM) and potent in vitro antagonistic activity (IC₅₀=2.18 nM). GnRH-R antagonist 1 can be used in studies of advanced prostate cancer and premature LH peaks preventing .

HY-119198

NSC745885	Apoptosis Histone Methyltransferase	Cancer
NSC745885 an effective anti-tumor agent, shows selective toxicity against multiple cancer cell lines but not normal cells. NSC745885 is an effective down-regulator of EZH2 via proteasome-mediated degradation. NSC745885 provides possibilities for the study of advanced bladder and oral squamous cell carcinoma (OSCC) cancers .

HY-136174

RBN-2397 5+ Cited Publications	PARP	Cancer
RBN-2397 is a potent, accross species and orally active NAD ⁺ competitive inhibitor of PARP7 (IC₅₀<3 nM). RBN-2397 selectively binds to PARP7 (K_d=0.001 μM) and restores IFN signaling. RBN-2397 has the potential for the study of advanced or metastatic solid tumors .

HY-129812

Borofalan	Isotope-Labeled Compounds	Cancer
Borofalan- ¹⁰B can be used for Boron neutron capture research (BNCT). Borofalan- ¹⁰B can be used for the research of recurrent or locally advanced head and neck cancer .

HY-15163

Zotiraciclib TG02; SB1317	JAK CDK FLT3	Cancer
Zotiraciclib (TG02) is an orally active potent inhibitor of CDK2, JAK2 and FLT3 with IC₅₀ values of 13, 73, and 56 nM, respectively. Zotiraciclib can be used for the research of advanced leukemias and multiple myeloma .

HY-14892A

Gemigliptin tartrate LC15-0444 tartrate	Dipeptidyl Peptidase	Metabolic Disease
Gemigliptin tartrate (LC15-0444 tartrate) is a highly selective, reversible and competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, with an IC₅₀ of 10.3 nM for human recombinant DPP-4. Gemigliptin tartrate exhibits potent anti-glycation properties. Gemigliptin tartrate can be used for the research of advanced glycation end products (AGE)-related diabetic complications .

HY-N0033

Poliumoside 2 Publications Verification	Aldose Reductase	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Poliumoside, a caffeoylated phenylpropanoid glycoside, is isolated from Brandisia hancei stems and leaves. Poliumoside is an advanced glycation end product (AGE) formation and rat lens aldose reductase (RLAR) inhibitor, with IC₅₀s of 19.69 and 8.47 μM, respectively. Poliumoside also has antiinflammatory and antioxidant activity .

HY-108943

Sabinene 1 Publications Verification	Others	Others
Sabinene is an naturally occurring bicyclic monoterpene which can be used as flavorings, perfume additives, fine chemicals, and advanced biofuels. Sabinene is also an orally active compound to attenuates skeletal muscle atrophy and regulates ROS-mediated MAPK/MuRF-1 pathways .

HY-P99052

Tislelizumab	PD-1/PD-L1	Inflammation/Immunology Cancer
Tislelizumab, a monoclonal antibody with high binding affinity to the PD-1 receptor, minimizes Fcγ receptor binding on macrophages, thereby abrogating antibody-dependent phagocytosis, a mechanism of T cell clearance and potential resistance to anti-PD-1 research. Tislelizumab can be used for the research of advanced squamous non-small-cell lung cancer .

HY-136255

Camizestrant 2 Publications Verification AZD-9833	Estrogen Receptor/ERR	Cancer
Camizestrant (AZD-9833) is a potent and orally active estrogen receptor (ER) antagonist. Camizestrant is used for the study of ER ⁺ HER2-advanced breast cancer .

HY-13582

Carbendazim 4 Publications Verification	Fungal Parasite	Infection Cancer
Carbendazim is a potent and orally active broad-spectrum benzimidazole fungicide and can be acts as a pesticide for fungal diseases research, such as Seproria, Fusarium and Sclerotina . Carbendazim is a benzimidazole (HY-Y1825) derivative with antitumor activity and used for cancer research, especially advanced solid tumors and lymphoma .

HY-N7426

3-Deoxyglucosone 3-Deoxy-D-glucosone	GLP Receptor	Metabolic Disease
3-Deoxyglucosone (3-Deoxy-D-glucosone) is a reactive intermediate of the Maillard reaction and the polyol pathway. 3-Deoxyglucosone rapidly reacts with protein amino groups to form advanced glycation end products (AGEs), such as imidazolone, it is the most specific AGE for 3-DG. 3-Deoxyglucosone synergizes with low glucose to potentiate GLP-1 secretion and is considered as a biomarker for diabetes .

HY-16215

Mipsagargin G-202	Drug-Linker Conjugates for ADC	Cancer
Mipsagargin (G-202) is a novel thapsigargin-based targeted proagent consisting of a prostate-specific membrane antigen (PSMA)-specific peptide coupled to an analog of the potent sarcoplasmic/endoplasmic reticulum calcium adenosine triphosphatase (SERCA) pump inhibitor Thapsigargin (HY-13433). Mipsagargin is activated by PSMA-mediated cleavage of an inert masking peptide. Mipsagargin has the potential for refractory, advanced or metastatic solid tumours research .

HY-145804

AZD-9574 1 Publications Verification	PPAR	Neurological Disease
AZD-9574 is a potent and brain penetrant PARP1 inhibitor and shows >8000-fold selectivity for PARP1 compared to PARP2/3/5a/6. AZD-9574 acts by selectively inhibiting and trapping PARP1 at the sites of SSBs. AZD-9574 is an anti-cancer agent and can be used for HRD ⁺ breast cancer and advanced solid malignancies research .

HY-106024B

Alagebrium chloride

1 Publications Verification

ALT711
Endogenous Metabolite Metabolic Disease

Alagebrium chloride (ALT711) is an advanced glycation end product (AGE) inhibitor.

Alagebrium chloride 1 Publications Verification ALT711	Endogenous Metabolite	Metabolic Disease
Alagebrium chloride (ALT711) is an advanced glycation end product (AGE) inhibitor.

HY-125538

Deoxybrevianamide E	Endogenous Metabolite	Inflammation/Immunology
Deoxybrevianamide E, an indole alkaloid, is a biosynthetic precursor for advanced metabolites isolated from the marine-derived Aspergillus sp. .

HY-P9971

Camrelizumab 1 Publications Verification SHR-1210	PD-1/PD-L1	Cancer
Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC₅₀ of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al .

HY-B1745

Pyridoxylamine 2 Publications Verification
Pyridoxylamine is an advanced glycation end production (AGEs) and lipoxidation end products (ALEs) inhibitor, to protect against diabetes-induced retinal vascular lesions.

HY-B1745A

Pyridoxylamine dihydrochloride 2 Publications Verification
Pyridoxylamine dihydrochloride is an advanced glycation end production (AGEs) and lipoxidation end products (ALEs) inhibitor, to protect against diabetes-induced retinal vascular lesions .

HY-137573

Trotabresib 1 Publications Verification CC-90010	Epigenetic Reader Domain	Cancer
CC-90010 (compound 1) is a reversible and orally active BET inhibitor. CC-90010 is applied in the study for advanced solid tumors .

HY-P9903

Nivolumab Maximum Cited Publications 16 Publications Verification BMS-936558; ONO-4538; MDX-1106	PD-1/PD-L1	Cancer
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

HY-108162A

Ataquimast	COX	Inflammation/Immunology
Ataquimast is a COX-2 inhibitor that inhibits the release of leukotrienes, TNF-α and GM-CSF. Ataquimast can be used in the study of advanced receptor-positive breast cancer .

HY-17557

Calcium N5-methyltetrahydrofolate 5 Publications Verification NSC173328; 5-Methyl THF calcium	Antifolate	Cancer
Calcium N5-methyltetrahydrofolate(NSC173328) is the calcium salt of levomefolic acid, which has been proposed for treatment of cardiovascular disease and advanced cancers such as breast and colorectal cancers.

HY-19708

KIRA6 10+ Cited Publications	IRE1	Metabolic Disease Inflammation/Immunology Cancer
KIRA6 is an advanced small-molecule IRE1α RNase kinase inhibitor with an IC₅₀ of 0.6 µM . KIRA6 can trigger an apoptotic response .

HY-N4089

Quercetin 3-gentiobioside	Aldose Reductase	Metabolic Disease
Quercetin 3-gentiobioside is isolated from A. iwayomogi, AR and AGE formation inhibitor, demonstrates biological activities against Aldose reductase (AR) and the formation of advanced glycation endproducts (AGEs) .

HY-137432

Avotaciclib BEY1107	CDK	Cancer
Avotaciclib (BEY1107) is a potent and orally active inhibitor of cyclin dependent kinase 1 (CDK1). Avotaciclib can be used for the research of locally advanced or metastatic pancreatic cancer .

HY-137432A

Avotaciclib trihydrochloride 1 Publications Verification BEY1107 trihydrochloride	CDK	Cancer
Avotaciclib (BEY1107) trihydrochloride is a potent and orally active inhibitor of cyclin dependent kinase 1 (CDK1). Avotaciclib trihydrochloride can be used for the research of locally advanced or metastatic pancreatic cancer .

HY-P99812

Ragifilimab INCAGN-1876	TNF Receptor	Cancer
Ragifilimab (INCAGN-1876) is an agonist monoclonal antibody targeting the glucocorticoid-induced TNFR-related protein (GITR). Ragifilimab can be used for advanced or metastatic solid tumors research .

HY-114231C

Exaluren sulfate ELX-02 sulfate; NB-124 sulfate	Others	Metabolic Disease
Exaluren (ELX-02) sulfate is an investigational, advanced synthetic eukaryotic ribosome selective glycoside (ERSG). Exaluren sulfate is being developed as a therapy for genetic diseases caused by nonsense mutations .

HY-114231B

Exaluren disulfate 1 Publications Verification ELX-02 disulfate; NB-124 disulfate	Others	Metabolic Disease
Exaluren (ELX-02) disulfate is an investigational, advanced synthetic eukaryotic ribosome selective glycoside (ERSG). Exaluren disulfate is being developed as a therapy for genetic diseases caused by nonsense mutations .

HY-76383

LR-90	Others	Metabolic Disease Inflammation/Immunology
LR-90 is an advanced glycation end product (AGE) inhibitor, inhibits inflammatory responses in human monocytes . LR-90 is also used in the research of diabetic animal model .

HY-P99785

Opucolimab HLX20	PD-1/PD-L1	Cancer
Opucolimab is an anti-PD-L1 recombinant human monoclonal antibody. Opucolimab can be used to synthesis antibody agent conjugates. Opucolimab can be used for the research of advanced solid tumors .

HY-108162

Ataquimast free base	COX	Inflammation/Immunology
Ataquimast free base is a COX-2 inhibitor that inhibits the release of leukotrienes, TNF-α and GM-CSF. Ataquimast free base can be used in the study of advanced receptor-positive breast cancer .

HY-P9903A

Nivolumab (anti-PD-1) Maximum Cited Publications 16 Publications Verification	PD-1/PD-L1	Cancer
Nivolumab (anti-PD-1) is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer .

HY-136362

ARRY-382	c-Fms	Inflammation/Immunology Cancer
ARRY-382 is a potent, oral and highly selective inhibitor of CSF1R/c-Fms with an IC₅₀ of 9 nM. ARRY-382 can be used for the research of advanced or metastatic cancers .

HY-W062697

HTL14242 HTL0014242	mGluR	Neurological Disease
HTL14242 (HTL0014242) is an advanced and orally active mGlu5 NAM with a pK_i and a pIC₅₀ of 9.3 and 9.2, respectively . HTL14242 can be used for the research of parkinson’s disease .

HY-127009

Levoleucovorin Levofolinic acid; Levofolene	Endogenous Metabolite	Cancer
Levoleucovorin (Levofolinic acid) is the pharmacologically active levoisomer of racemic leucovorin. Levoleucovorin can be used as a rescue agent after high-dose Methotrexate (HY-14519) therapy, and in combination with fluorouracil for the research of advanced metastatic colorectal cancer .

HY-137346

DD-03-156 (S,R,S)-AHPC-Me-PEG2-dabrafenib	CDK LIM Kinase (LIMK)	Cancer
DD-03-156 is a potent and selective degrader of CDK17 and LIMK2. The selectivity and potency of DD-03-156 is exquisite and makes an advanced starting point for the development of a chemical probe for the degradation of CDK17 .

Cat. No.	Product Name

HY-L0094V

Chinese National Compound Library	1,398,968 compounds
The Chinese National Compound Library (CNCL) composes 1.4 million compounds possessing diversified structures. Coupled with this library will be advanced sample handling, information management and quality control systems. Most compounds in the library are drug-like, conforming to “Lipinski’s Rule of Five”, such as MW < 500, logP < 5, Hydrogen Bond Donors < 5.

HY-L179

Radiosensitizer Library

41 Compounds compounds

Radiotherapy is a common treatment for various cancers, and more than 50% of cancer patients require radiotherapy during the disease treatment. With advances in radiation technology and a better understanding of tumor biology, the efficacy of radiation therapy has gradually improved, and more and more patients have benefited from it. However, even with the use of advanced radiotherapy techniques, there are still many malignant tumor cells with low sensitivity to radiation, leading to the radiation effect is not ideal. To solve this problem, radiosensitizers have received more and more attention. Radiosensitizer is a kind of drug that can enhance the radiosensitivity of tumor cells and improve the effect of radiotherapy. Radiation sensitizers act in a variety of ways, such as killing hypoxic cells, enhancing DNA damage, inhibiting DNA damage repair, and blocking cell cycle progression, making tumor cells more susceptible to radiation damage and death than surrounding normal cells.

MCE designs a unique collection of 41 compounds with definite reported radiosensitization. It can be used for drug combination research in anti-cancer treatment.

HY-L077

Anti-Pancreatic Cancer Compound Library

2695 compounds

Pancreatic cancer is a devastating disease with a low overall survival rate. Chemotherapy is the most common treatment for patients presenting with advanced pancreatic cancer. More recently, the era of targeted therapies has generated a lot of interest in discovering better approaches for patients with pancreatic cancer. Commonly mutated genes in pancreatic cancer include K-ras (in 74-100% of cases), p16INK4a (up to 98%), p53 (43 to 76%), DPC4 (about 50%), HER-2/neu (in about 65%) and FHIT (found in 70% of cases). Other genes involved are notch1, Akt-2, BRCA2 and COX-2. These proteins are important targets of target therapies for pancreatic cancer.

MCE offers a unique collection of 2695 compounds with identified and potential anti- pancreatic cancer activity. These compounds target K-Ras, p53, HER2, Notch, AKT, etc. MCE anti-pancreatic cancer compound library is a useful tool for anti-pancreatic cancer drugs screening and other related research.

Cat. No.	Product Name	Type

HY-130502

Cholesterol 5beta,6beta-epoxide

Cholesterol beta-epoxide

Biochemical Assay Reagents

Cholesterol 5beta,6beta-epoxide is an oxidative metabolite of cholesterol formed by free-radical and non-radical oxidation of cholesterol at the 5,6 double bond. Induces lactate dehydrogenase (LDH) release and apoptosis in macrophage-differentiated U937 cells. Cholesterol 5beta,6beta-epoxide has been found in human fatty streaks and advanced atherosclerotic lesions, but not in normal aortic tissue .

Cat. No.	Product Name	Target	Research Area

HY-16050

Plitidepsin 2 Publications Verification Aplidine; PM90001	DNA/RNA Synthesis SARS-CoV	Infection Cancer
Plitidepsin (Aplidine) is a potent anti-cancer agent by targeting eEF1A2 ( K_D=80 nM) . Plitidepsin possesses antiviral activity and is against SARS-CoV-2 with an IC₉₀ of 0.88 nM. Plitidepsin is usually used for multiple myeloma and advanced cancer research, and has the potential for COVID-19 research .

HY-P2268

RAGE antagonist peptide 2 Publications Verification	Amyloid-β	Inflammation/Immunology Cancer
RAGE antagonist peptide is an advanced glycation end products (RAGE) antagonist. RAGE antagonist peptide prevents RAGE from binding with several of its most important ligands, including HMGB-1, S100P, and S100A4. RAGE antagonist peptide (RAP) possesses anti-tumor and anti-inflammatory activities .

HY-16215

Mipsagargin G-202	Drug-Linker Conjugates for ADC	Cancer
Mipsagargin (G-202) is a novel thapsigargin-based targeted proagent consisting of a prostate-specific membrane antigen (PSMA)-specific peptide coupled to an analog of the potent sarcoplasmic/endoplasmic reticulum calcium adenosine triphosphatase (SERCA) pump inhibitor Thapsigargin (HY-13433). Mipsagargin is activated by PSMA-mediated cleavage of an inert masking peptide. Mipsagargin has the potential for refractory, advanced or metastatic solid tumours research .

HY-P2713

OM99-2	Beta-secretase	Neurological Disease
OM99-2, an eight residue peptidomimetic, tight-binding inhibitor of human brain memapsin 2 with a K_i value of 9.58 nM . OM99-2 is significantly advanced the development of BACE1 inhibitor . OM99-2 has the potential for the research of the Alzheimer's disease .

HY-P2713A

OM99-2 TFA	Beta-secretase	Neurological Disease
OM99-2 TFA, an eight residue peptidomimetic, tight-binding inhibitor of human brain memapsin 2 with a K_i value of 9.58 nM . OM99-2 TFA is significantly advanced the development of BACE1 inhibitor . OM99-2 has the potential for the research of the Alzheimer's disease .

HY-P2268A

RAGE antagonist peptide TFA 2 Publications Verification	Amyloid-β	Inflammation/Immunology Cancer
RAGE antagonist peptide TFA is an advanced glycation end products (RAGE) antagonist. RAGE antagonist peptide TFA prevents RAGE from binding with several of its most important ligands, including HMGB-1, S100P, and S100A4. RAGE antagonist peptide TFA possesses anti-tumor and anti-inflammatory activities .

Cat. No.	Product Name

HY-K0510A

RT Master Mix for qPCR II 50+ Cited Publications
MCE RT Master Mix for qPCR II is a convenient, ready-to-use formulation for reverse transcription. With advanced reverse transcriptase, this kit can synthesize cDNA more rapidly, more specifically.

Cat. No.	Product Name	Target	Research Area

HY-P99807

Prolgolimab BCD-100	PD-1/PD-L1	Cancer
Prolgolimab (BCD-100) is a human IgG1 anti-PD-1 monoclonal antibody containing the Fc-silencing 'LALA' mutation. Prolgolimab can be used for the research of advanced melanoma .

HY-P99052

Tislelizumab	PD-1/PD-L1	Inflammation/Immunology Cancer
Tislelizumab, a monoclonal antibody with high binding affinity to the PD-1 receptor, minimizes Fcγ receptor binding on macrophages, thereby abrogating antibody-dependent phagocytosis, a mechanism of T cell clearance and potential resistance to anti-PD-1 research. Tislelizumab can be used for the research of advanced squamous non-small-cell lung cancer .

HY-P9971

Camrelizumab 1 Publications Verification SHR-1210	PD-1/PD-L1	Cancer
Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC₅₀ of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al .

HY-P9903

Nivolumab Maximum Cited Publications 16 Publications Verification BMS-936558; ONO-4538; MDX-1106	PD-1/PD-L1	Cancer
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

HY-P99475

Betifisolimab MSB-2311	PD-1/PD-L1	Cancer
Betifisolimab (MSB-2311) is a humanized monoclonal antibody directed against the immunosuppressive ligand PD-L1. Betifisolimab has the potential for advanced solid tumors and hematological malignancies research .

HY-P99812

Ragifilimab INCAGN-1876	TNF Receptor	Cancer
Ragifilimab (INCAGN-1876) is an agonist monoclonal antibody targeting the glucocorticoid-induced TNFR-related protein (GITR). Ragifilimab can be used for advanced or metastatic solid tumors research .

HY-P99785

Opucolimab HLX20	PD-1/PD-L1	Cancer
Opucolimab is an anti-PD-L1 recombinant human monoclonal antibody. Opucolimab can be used to synthesis antibody agent conjugates. Opucolimab can be used for the research of advanced solid tumors .

HY-P9903A

Nivolumab (anti-PD-1) Maximum Cited Publications 16 Publications Verification	PD-1/PD-L1	Cancer
Nivolumab (anti-PD-1) is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer .

HY-P99401

Rosmantuzumab OMP-131R10	Inhibitory Antibodies	Cancer
Rosmantuzumab (OMP-131R10) is an anti-R-spondin 3 (RSPO3) humanized monoclonal antibody. Rosmantuzumab can be used for the research of advanced telapsed and refractory solid tumors .

HY-P99364

Icrucumab Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1	VEGFR	Cancer
Icrucumab (Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1) is a human Anti-VEGFR-1 IgG1 monoclonal antibody. Icrucumab has the potential for the research of advanced solid tumors .

HY-P99594

Socazolimab ZKAB001; STI-1014; STI-A1014	PD-1/PD-L1	Cancer
Socazolimab (ZKAB001) is an anti-PD-L1 monoclonal antibody. Socazolimab has lasting safety and efficacy in the treatment of recurrent or metastatic cervical cancer. Socazolimab also has potential applications in small cell lung cancer, esophageal squamous cell carcinoma (ESCC), advanced urothelial carcinoma and osteosarcoma .

HY-P99708

Livmoniplimab ABBV-151; ARGX-115	TGF-beta/Smad	Cancer
Livmoniplimab (ABBV-151; ARGX-115) is a potent, humanized monoclonal antibody against the LRRC32 (GARP)/TGFβ1 complex. Livmoniplimab blocks LRRC32-mediated latent TGFβ1 activation and release. Livmoniplimab has potential in cancer research as a single anticancer agent or in combination with an anti-PD-1 mAb to inhibit locally advanced or metastatic solid tumors (NCT03821935) .

HY-P99463

Batiraxcept AVB-S6-500	TAM Receptor	Cancer
Batiraxcept (AVB-S6-500) is a highly potent and specific AXL inhibitor, a recombinant fusion protein dimer containing the extracellular domain of human AXLM and human immunoglobulin G1 heavy chain (Fc). Batiraxcept binds to GAS6 and inhibits the interaction of GAS6 with AXL, thereby substantially reducing AXL signaled invasion and migration of highly metastatic cells in vitro and inhibiting metastatic disease in nonclinical models of aggressive human cancers. Batiraxcept is available for studies in advanced or metastatic clear cell renal cell carcinoma (ccRCC) and platinum sensitive recurrent ovarian cancer .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-16050

Plitidepsin 2 Publications Verification Aplidine; PM90001	Structural Classification Microorganisms Marine natural products Source classification Other marine organisms	DNA/RNA Synthesis SARS-CoV
Plitidepsin (Aplidine) is a potent anti-cancer agent by targeting eEF1A2 ( K_D=80 nM) . Plitidepsin possesses antiviral activity and is against SARS-CoV-2 with an IC₉₀ of 0.88 nM. Plitidepsin is usually used for multiple myeloma and advanced cancer research, and has the potential for COVID-19 research .

HY-N7628

Cassiaside C Toralactone 9-O-β-D-gentiobioside	Structural Classification Monophenols Classification of Application Fields Leguminosae Source classification Phenols Metabolic Disease Cassia tora Linn. Plants Disease Research Fields	Endogenous Metabolite
Cassiaside C (Toralactone 9-O-β-D-gentiobioside) is a naphthopyrone isolated from the seed of Cassia tora and has inhibitory activity on advanced glycation end products (AGE) formation in vitro .

HY-N0033

Poliumoside 2 Publications Verification	Cardiovascular Disease Classification of Application Fields Source classification Callicarpa formosana Rolfe Plants Simple Phenylpropanols Verbenaceae Phenols Polyphenols Scrophulariaceae Phenylpropanoids Inflammation/Immunology Disease Research Fields Brandisia hancei Hook. f.	Aldose Reductase
Poliumoside, a caffeoylated phenylpropanoid glycoside, is isolated from Brandisia hancei stems and leaves. Poliumoside is an advanced glycation end product (AGE) formation and rat lens aldose reductase (RLAR) inhibitor, with IC₅₀s of 19.69 and 8.47 μM, respectively. Poliumoside also has antiinflammatory and antioxidant activity .

HY-108943

Sabinene 1 Publications Verification	Other Monoterpenes other families Classification of Application Fields Terpenoids Source classification Other Diseases Plants Disease Research Fields	Others
Sabinene is an naturally occurring bicyclic monoterpene which can be used as flavorings, perfume additives, fine chemicals, and advanced biofuels. Sabinene is also an orally active compound to attenuates skeletal muscle atrophy and regulates ROS-mediated MAPK/MuRF-1 pathways .

HY-N7426

3-Deoxyglucosone 3-Deoxy-D-glucosone	Structural Classification Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Saccharides	GLP Receptor
3-Deoxyglucosone (3-Deoxy-D-glucosone) is a reactive intermediate of the Maillard reaction and the polyol pathway. 3-Deoxyglucosone rapidly reacts with protein amino groups to form advanced glycation end products (AGEs), such as imidazolone, it is the most specific AGE for 3-DG. 3-Deoxyglucosone synergizes with low glucose to potentiate GLP-1 secretion and is considered as a biomarker for diabetes .

HY-106024B

Alagebrium chloride 1 Publications Verification ALT711	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Alagebrium chloride (ALT711) is an advanced glycation end product (AGE) inhibitor.

HY-125538

Deoxybrevianamide E	Alkaloids Structural Classification Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Source classification Marine natural products Endogenous metabolite Inflammation/Immunology Disease Research Fields Marine microorganism Indole Alkaloids	Endogenous Metabolite
Deoxybrevianamide E, an indole alkaloid, is a biosynthetic precursor for advanced metabolites isolated from the marine-derived Aspergillus sp. .

HY-N4089

Quercetin 3-gentiobioside	Flavonols Flavonoids other families Classification of Application Fields Source classification Phenols Polyphenols Metabolic Disease Plants Disease Research Fields	Aldose Reductase
Quercetin 3-gentiobioside is isolated from A. iwayomogi, AR and AGE formation inhibitor, demonstrates biological activities against Aldose reductase (AR) and the formation of advanced glycation endproducts (AGEs) .

HY-N12071

Lucidin-ω-Me ether	Quinones Structural Classification Anthraquinones Source classification Rubiaceae Knoxia valerianoides Thorel ex Pitard Plants	Others
Lucidin-ω-Me ether (Compound 2) can be isolated from the roots of Knoxia valerianoides. Lucidin-ω-Me ether inhibits the advanced glycation end products (AGEs) formation in vitro(IC₅₀: 62.79 μM) .

HY-N7069

4-Isopropylbenzyl alcohol	Camellia nitidissima Natural Products Classification of Application Fields Source classification Plants Disease Research Fields Cancer Theaceae	Others
4-Isopropylbenzyl alcohol is a chemical composition of the essential oils from the leaves and flowers of Camellia nitidissima. C. nitidissima possess multiple biological activities including antioxidant activity, anticancer activity, and cytotoxicity as well as inhibiting the formation of advanced glycation end-products .

HY-N8375

Sieboldin	Structural Classification Source classification Balanophora involucrata Hook. f. Plants Balanophoraceae Saccharides Monosaccharides	Others
Sieboldin is a dihydrochalcone, which inhibits the production of advanced glycation end products (AGE) produced by bovine serum albumins (BSA), has free radical scavenging activity and cytotoxicity in cancer cell lines, and is also used to capture of methylglyoxal (MGO) from Malus baccata .

HY-114988

PGE-M tetranor-PGEM	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields Cancer	Endogenous Metabolite
PGE-M is a metabolite of prostaglandin E₂ (PEG₂) as a biomarker of inflammation and cancer including advanced colorectal neoplasia, ovarian cancer, prostate cancer and so on. Urinary PGE-M is positively associated with obesity, smoking and lung metastases with breast cancer .

HY-N0022

Isoacteoside 3 Publications Verification Isoverbascoside	Classification of Application Fields Simple Phenylpropanols Source classification Cistanche deserticola Ma Phenols Polyphenols Metabolic Disease Orobanchaceae Phenylpropanoids Plants Disease Research Fields	Others
Isoacteoside is a natural compound which exhibit significant inhibition of advanced glycation end product formation with IC50 values of 4.6-25.7 μM, compared with those of aminoguanidine (IC50=1,056 μM) and quercetin (IC50=28.4 μM) as positive controls.

HY-114883

Homocarnosine L-Homocarnosine; γ-Aminobutyryl-L-histidine	Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields	GABA Receptor Endogenous Metabolite
Homocarnosine is a dipeptide of γ-aminobutyric acid (GABA) and histidine unique to brain. Homocarnosine is an inhibitory neuromodulator synthesized in the neuron from GABA and exhibiting anticonvulsant effects .Homocarnosine has antioxidant and anti-inflammatory actions, prevention of DNA damage, and inhibition of advanced glycation end-product formation .

HY-114883A

Homocarnosine TFA L-Homocarnosine TFA; γ-Aminobutyryl-L-histidine TFA	Structural Classification Natural Products Neurological Disease Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields	GABA Receptor Endogenous Metabolite
Homocarnosine TFA is a dipeptide of γ-aminobutyric acid (GABA) and histidine unique to brain. Homocarnosine TFA is an inhibitory neuromodulator synthesized in the neuron from GABA and exhibiting anticonvulsant effects . Homocarnosine TFA has antioxidant and anti-inflammatory actions, prevention of DNA damage, and inhibition of advanced glycation end-product formation .

HY-N6883

6-Methoxytricin	Flavonoids other families Classification of Application Fields Flavones Source classification Phenols Polyphenols Metabolic Disease Plants Disease Research Fields	Aldose Reductase
6-Methoxytricin (Compound 6) is an flavonoid isolated from Artemisia iwayomogi. 6-Methoxytricin (Compound 6) is an inhibitor on aldose reductase (AR) and advanced glycation endproduct (AGE) formation activities with IC₅₀ values of 30.29 μM and 134.88 μM, respectively. 6-Methoxytricin (Compound 6) has potential as an anti-diabetic complications agent .

HY-N4170

Chebulic acid 1 Publications Verification	Classification of Application Fields Ketones, Aldehydes, Acids Combretaceae Source classification Phenols Polyphenols Metabolic Disease Terminalia chebula Retz. Plants Disease Research Fields	Others
Chebulic acid, a phenolcarboxylic acid compound isolated from Terminalia chebula, has potent anti-oxidant activity, which breaks the cross-links of proteins induced by advanced glycation end-products (AGEs) and inhibits the formation of AGEs. Chebulic acid is effective in controlling elevated metabolic parameters, oxidative stress and renal damage, supporting its beneficial effect in diabetic nephropathy .

Species:	Human (3) Mouse (1) Cynomolgus (1)
Tag:	His (3) Tag Free (1) Fc (1)
Source:	HEK293 (4) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P74425

	AGER Protein, Mouse (HEK293, His) Advanced glycosylation end product-specific receptor; Ager; Rage	Mouse	HEK293
	AGER proteins have multiple activities, including binding to S100 proteins, advanced glycation end products, and heparin. It is involved in cellular responses to amyloid, regulation of synaptic potentiation, and cytokine production. AGER Protein, Mouse (HEK293, His) is the recombinant mouse-derived AGER protein, expressed by HEK293 , with C-His labeled tag. The total length of AGER Protein, Mouse (HEK293, His) is 319 a.a., with molecular weight of ~50 kDa.

HY-P74604

	AGER Protein, Human (HEK293, hFc) Advanced glycosylation end product-specific receptor; Ager; Rage	Human	HEK293
	AGER proteins are cell surface pattern recognition receptors that expertly sense endogenous stress signals utilizing an extensive library of ligands, including advanced glycation end products, S100 proteins, high mobility Group Box 1 proteins/HMGB1, starch Like protein β/APP oligomers, nucleic acids, phospholipids, and glycosaminoglycans. AGER Protein, Human (HEK293, hFc) is the recombinant human-derived AGER protein, expressed by HEK293 , with C-hFc labeled tag. The total length of AGER Protein, Human (HEK293, hFc) is 321 a.a., with molecular weight of approximately 76.18 kDa.

HY-P700146AF

	Animal-Free AGER Protein, Human (His) Advanced glycosylation end product-specific receptor; Ager; RAGE	Human	E. coli
	AGER proteins are cell surface pattern recognition receptors that expertly sense endogenous stress signals utilizing an extensive library of ligands, including advanced glycation end products, S100 proteins, high mobility Group Box 1 proteins/HMGB1, starch Like protein β/APP oligomers, nucleic acids, phospholipids, and glycosaminoglycans. Animal-Free AGER Protein, Human (His) is the recombinant human-derived animal-FreeAGER protein, expressed by E. coli , with C-His labeled tag. The total length of Animal-Free AGER Protein, Human (His) is 278 a.a., with molecular weight of ~30.94 kDa.

HY-P74605

	AGER Protein, Human (HEK293) Advanced glycosylation end product-specific receptor; Ager; Rage	Human	HEK293
	AGER proteins are cell surface pattern recognition receptors that expertly sense endogenous stress signals utilizing an extensive library of ligands, including advanced glycation end products, S100 proteins, high mobility Group Box 1 proteins/HMGB1, starch Like protein β/APP oligomers, nucleic acids, phospholipids, and glycosaminoglycans. AGER Protein, Human (HEK293) is the recombinant human-derived AGER protein, expressed by HEK293 , with tag free. The total length of AGER Protein, Human (HEK293) is 322 a.a., with molecular weight of 46-52 kDa.

HY-P701085

	AGER Protein, Cynomolgus (HEK293, His) Advanced glycosylation end-product specific receptor; AGER; RAGE; SCARJ1	Cynomolgus	HEK293
	AGER protein is a cell surface pattern recognition receptor that can sense endogenous stress signals from a variety of ligands, such as S100 protein, HMGB1, β-amyloid, etc. AGER Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived AGER protein, expressed by HEK293 , with C-His labeled tag. The total length of AGER Protein, Cynomolgus (HEK293, His) is 331 a.a., with molecular weight of 50-65 kDa.

Cat. No.	Product Name	Chemical Structure

HY-129812

Borofalan

Borofalan- ¹⁰B can be used for Boron neutron capture research (BNCT). Borofalan- ¹⁰B can be used for the research of recurrent or locally advanced head and neck cancer .

HY-13582S

Carbendazim-d4

Carbendazim-d₄ is the deuterium labeled Carbendazim. Carbendazim is a potent and orally active broad-spectrum benzimidazole fungicide and can be acts as a pesticide for fungal diseases research, such as Seproria, Fusarium and Sclerotina[1][3]. Carbendazim is a benzimidazole (HY-Y1825) derivative with antitumor activity and used for cancer research, especially advanced solid tumors and lymphoma[3].

HY-13342AS

Apatinib-d8 free base

Apatinib-d₈ (free base) is the deuterium labeled Apatinib free base[1]. Apatinib free base (YN968D1 free base) is an orally bioavailable tyrosine kinase inhibitor, which selectively targets VEGFR-2 (IC50=1 nM). Apatinib free base (YN968D1 free base) is an anti-angiogenic drug for the research of advanced or metastatic gastric cancer. Apatinib free base (YN968D1 free base) potently inhibits Ret, c-Kit and c-Src with IC50s of 13, 429 and 530 nM, respectively. It also inhibits cellular phosphorylation of VEGFR-2, c-kit and PDGFRβ[2][3][4].

Cat. No.	Product Name	Application	Reactivity

HY-P81087

AGEs Antibody Advanced glycosylation end products; AGE.	WB; ELISA; IHC-P; IHC-F; Flow-Cyt; IF	Human, Mouse, Rat,
AGEs Antibody is an unconjugated, rabbit-derived, anti-AGEs polyclonal antibody. AGEs Antibody can be used for: WB, ELISA, IHC-P, IHC-F, Flow-Cyt, IF expriments in human, mouse, rat, background without labeling.

HY-P81086

RAGE Antibody Advanced glycosylation end product specific receptor; Advanced glycosylation end product-specific receptor; AGER; EC 2.7.11.22; LE 9211 A antigen; LE-9211-A antigen; MGC22357; MOK; RAGE 1; RAGE1; MOK protein kinase; Receptor for Advanced glycation endproducts; Renal tumor antigen 1; Renal tumor antigen; Renal cell carcinoma antigen (MOK protein kinase); Renal tumor antigen 1; RAGE_HUMAN.	WB; ELISA; IHC-P; IHC-F; Flow-Cyt; IF	Human, Mouse, Rat,
RAGE Antibody is an unconjugated, approximately 42 kDa, rabbit-derived, anti-RAGE polyclonal antibody. RAGE Antibody can be used for: WB, ELISA, IHC-P, IHC-F, Flow-Cyt, IF expriments in human, mouse, rat, background without labeling.

Cat. No.	Product Name		Classification

HY-16373

CP-609754 LNK-754; OSI-754		Alkynes
CP-609754 (LNK-754) is a potent and reversible farnesyltransferase inhibitor with potential anticancer activity.The IC₅₀ for inhibiting farnesylation of recombinant human H-Ras is 0.57 ng/mL and recombinant K-Ras is 46 ng/mL . CP-609754 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

MCE Kits

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Advanced

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

MCE Kits

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Natural
Products